Hepatitis C News and Research

Latest Hepatitis C News and Research

HemoBioTech receives patent for HemoTech treatment of acute blood loss

HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.

29 Jul 2010

Pharmasset announces data from PSI-352938 single ascending dose study

Pharmasset, Inc. announced today that safety and pharmacokinetic data from the PSI-352938 single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.

28 Jul 2010

Positive results from study with Genome Sequencer FLX System for HIV drug-resistant mutation detection

454 Life Sciences, a Roche Company, has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.

28 Jul 2010

Roche to present diagnostics testing solutions at 2010 Clinical Lab Expo

Roche is featuring a diverse portfolio of diagnostics testing solutions for healthcare professionals in booth #2808 at the AACC/CSCC 2010 Clinical Lab Expo here, July 27-29 – and it's giving them a unique way to see firsthand where their own "dream lab" might take them.

From Roche Sequencing and Life Science 28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

35 cases of hepatitis C among Melbourne abortion clinic patients

Over the last few months there has been a rise in hepatitis C cases at an abortion clinic in Melbourne. In a new development 13 new cases have been diagnosed. This brings the total count to 35. The Victorian police are investigating the source of the infections. The link between the Croydon Day Surgery and the cluster was first revealed in April, when there were only 12 cases.

28 Jul 2010

InterMune second-quarter total revenue decreases to $5.9 million

InterMune, Inc. today announced results from operations for the second quarter and six months ended June 30, 2010. InterMune also highlighted its recent clinical development and business activities, and provided forward-looking financial guidance for 2010.

28 Jul 2010

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

The Singaporean government's emphasis on raising awareness on the benefit of frequent health check-ups have significantly raised the number of Hepatitis C Virus (HCV) diagnosed cases in the country, expanding the patient pool. Therapeutics companies have a challenging task ahead for improving treatment for this market as current treatment requires high dosage frequency, but potentially has serious side effects.

27 Jul 2010

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

On the final day of the International AIDS Conference-AIDS 2010 Friday, Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria called upon "China, India and other fast-growing economies" to chip in to help close the funding gap in efforts to battle HIV/AIDS, Agence France-Presse reports. "Until now, these countries have been recipients of AIDS funds, not donors," the news service writes.

27 Jul 2010

Idenix second-quarter total revenues decrease to $1.3 million

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2010. At June 30, 2010, Idenix's cash and cash equivalents totaled $51.0 million.

27 Jul 2010

UCLA Health System launches hand transplantation program

The UCLA Health System has launched the new UCLA Hand Transplantation Program, the first of its kind on the West Coast and only the fourth such center in the United States. The program will help those who have suffered the traumatic loss of a hand or forearm and allow them to regain function and improve their quality of life. Qualified candidates are now being sought for a clinical study of the procedure.

27 Jul 2010

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.

26 Jul 2010

Securing universal access to HIV prevention, care, treatment and support

The biennial meeting of the global AIDS community concluded today with clear evidence of tangible progress in HIV research and programme scale up, yet facing an urgent need for increased resources, the protection of human rights, and broader use of scientifically sound prevention strategies. Delegates and organizers depart Vienna - where the conference opened 18 July under the theme of Rights Here, Right Now -- with a renewed commitment to push for securing universal access to HIV prevention, care, treatment and support.

23 Jul 2010

Vienna Declaration signed to support evidence-based drug policy for improving community health

Sandra Roelofs, First Lady of Georgia; George Tsereteli, Georgia's Deputy Chairman of Parliament; and Irakli Giorgobiani, Georgia's Vice Minister of Labour, Health and Social Affairs, today signed the Vienna Declaration, the official declaration of the XVIII International AIDS conference in Vienna, Austria.

23 Jul 2010

New model for scaling up treatment, prevention of HIV amongst IDUs

Against the backdrop of some of the globe's fastest growing HIV epidemics in Eastern Europe and Central Asia, a report launched today at the XVIII International AIDS conference in Vienna makes the case for a new model for scaling up treatment and prevention of HIV amongst Injecting Drug Users.

23 Jul 2010

Early HAART during TB treatment prolongs survival of untreated HIV-infected adults: CAMELIA study

A clinical trial in Cambodia has found it possible to prolong the survival of untreated HIV-infected adults with very weak immune systems and newly diagnosed tuberculosis (TB) by starting anti-HIV therapy two weeks after beginning TB treatment, rather than waiting eight weeks, as has been standard.

23 Jul 2010

NVHR releases statement on New York Times article 'Hope against Hepatitis C'

In response to today's New York Times article, "Hope against Hepatitis C," Andrew Muir, M.D., M.H.S., Director, Gastroenterology/Hepatology Research, Duke Clinical Research Institute and Steering Committee Member of the National Viral Hepatitis Roundtable (NVHR) released the following statement:

23 Jul 2010

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.

23 Jul 2010

Human Genome Sciences second-quarter revenues increase to $38.8 million

Human Genome Sciences, Inc. today announced financial results for the quarter ended June 30, 2010, and provided highlights of recent key developments.

23 Jul 2010

Reusing syringes in anesthesia leads to viral transmission: Study

Hepatitis B virus and hepatitis C virus can be transmitted during intravenous administration of anesthesia, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute. In this study, doctors found that anesthesia contamination - not endoscopy contamination - was the cause of infection.

23 Jul 2010